Renovacor (Renovacor) Days Sales Outstanding : 0.00 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Renovacor Days Sales Outstanding?

Renovacor's average Accounts Receivable for the three months ended in Sep. 2022 was $0.00 Mil. Renovacor's Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

The historical rank and industry rank for Renovacor's Days Sales Outstanding or its related term are showing as below:

RCOR's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.34
* Ranked among companies with meaningful Days Sales Outstanding only.

Renovacor's Days Sales Outstanding stayed the same from Sep. 2021 (0.00) to Sep. 2022 (0.00).

Renovacor Days Sales Outstanding Historical Data

The historical data trend for Renovacor's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Days Sales Outstanding Chart

Renovacor Annual Data

Trend

Dec20

Dec21

Days Sales Outstanding

Renovacor Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Sales Outstanding	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Renovacor's Days Sales Outstanding

For the Biotechnology subindustry, Renovacor's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renovacor's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Renovacor's Days Sales Outstanding falls into.

Renovacor Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Renovacor's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

	Days Sales Outstanding (A: Dec. 2021 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Renovacor's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding (Q: Sep. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Sep. 2022 ))	/	count )	/	Revenue (A: Sep. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Renovacor (AMEX:RCOR) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Renovacor Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Renovacor's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovacor (Renovacor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 8142, Greenwich, CT, USA, 06836

Website

https://www.renovacor.com

Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Executives

Joseph S Carroll	officer: Chief Accounting Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino	director	C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr.	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll	officer: Chief Financial Officer
Jonas Grossman	director	17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook	director, officer: Chief Executive Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen	officer: Chief Scientific Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran	officer: Chief Medical Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco	officer: Interim CFO